Latest group publications
- C9orf72-ALS human iPSC microglia are pro-inflammatory and toxic to co-cultured motor neurons via MMP9 22 September 2023 Björn F Vahsen
- Hypoxia dampens innate immune signalling at early time points and increases Zika virus RNA levels in iPSC-derived macrophages 16 August 2023 Mirjam Schilling
- Zika virus-induces metabolic alterations in fetal neuronal progenitors that could influence in neurodevelopment during early pregnancy 24 April 2023 Javier Gilbert-Jaramillo
- Post-translational proteomics platform identifies neurite outgrowth impairments in Parkinson's disease GBA-N370S dopamine neurons 4 March 2023 Helle Bogetofte
- Broadly neutralizing aptamers to SARS-CoV-2: A diverse panel of modified DNA antiviral agents 30 January 2023 Amy D Gelinas
- Density dependent regulation of inflammatory responses in macrophages 2 January 2023 Alun Vaughan-Jackson
- Type I interferon receptor (<em>IFNAR2</em>) deficiency reveals Zika virus cytopathicity in human macrophages and microglia 28 November 2022 Aidan T Hanrath
- Radical-SAM dependent nucleotide dehydratase (SAND), rectification of the names of an ancient iron-sulfur enzyme using NC-IUBMB recommendations 17 November 2022 Yuxuan Ji
- Single-cell transcriptomics defines an improved, validated monoculture protocol for differentiation of human iPSC to microglia 14 November 2022 Sam J Washer
- Microglia states and nomenclature: A field at its crossroads 3 November 2022 Rosa C Paolicelli
Search
Site Admin
Szymon Stodolak
DPhil Student | szymon.stodolak@path.ox.ac.uk

Szymon is a DPhil student in Interdisciplinary Bioscience (BBSRC DTP in collaboration with Eli Lilly).
Neurodegenerative diseases, especially Alzheimer’s and Parkinson’s, affect millions of people worldwide. Unfortunately, there has been little to no success in developing treatments to prevent the onset or slow the progress of these diseases. Inflammation within the central nervous system can affect the course of neurodegenerative diseases, but – at the moment – we lack a representative human in vitro system to suitably mirror the neuroinflammatory state. Induced Pluripotent Stem Cells (iPSCs) can be generated from human donor skin or blood cells and turned into different brain cell types.
Szymon’s project will address the above limitation by culturing different human iPSC brain cell types together in a three-dimensional scaffold, including brain immune cells, microglia. This will enable us to study neuroinflammation and neurodegeneration ‘in a dish’. Szymon graduated from The University of Nottingham (MSci Neuroscience). During his studies, he developed an interest in cell culture models by working on in vitro conditions which could promote stem cell characteristics in cancer cells (thanks to Dr Dr. Androutsellis-Theotokis). During a placement year at the Alzheimer’s Research UK Drug Discovery Institute at University College London, he was focusing on culturing primary rat microglia in serum free conditions (thanks to Dr Lorenza Magno). When finishing off the time in Nottingham, his MSci thesis indicated that a polygenic risk score generated from microglial genes can partly predict the risk of developing Alzheimer’s disease (thanks to Prof Kevin Morgan).